Gemcitabine-Capecitabine Adjuvant Therapy Prolongs Survival in Pancreatic Adenocarcinoma
核心洞察
Adjuvant gemcitabine-capecitabine (GemCap) demonstrates prolonged overall survival compared to gemcitabine alone in pancreatic adenocarcinoma (搜索) patients.
Median overall survival was 31.6 months with GemCap versus 28.4 months with gemcitabine monotherapy (HR=0.83, P=0.031).
In patients with R0 resection, GemCap significantly improved median overall survival to 49.9 months compared to 32.2 months with gemcitabine (HR=0.63, P=0.002).
A long-term analysis of the phase III ESPAC4 trial reveals that adjuvant gemcitabine-capecitabine (GemCap) significantly improves overall survival compared to gemcitabine monotherapy in patients with pancreatic adenocarcinoma (搜索). The study, published in the Journal of Clinical Oncology, highlights the potential of GemCap as a standard adjuvant treatment option, especially for patients ineligible for mFOLFIRINOX.
The open-label trial, conducted across multiple sites in Europe, randomized 730 patients between November 2008 and September 2014 to receive either adjuvant GemCap (n = 364) or gemcitabine (n = 366). The overall survival analysis was performed after a median follow-up of 104 months (95% CI = 101–108 months).
Survival Benefits of Gemcitabine-Capecitabine
The median overall survival among all patients was 29.5 months (95% CI = 27.5–32.1 months). Specifically, the GemCap arm showed a median overall survival of 31.6 months (95% CI = 26.5–38.0 months), while the gemcitabine arm showed 28.4 months (95% CI = 25.2–32.0 months), resulting in a hazard ratio of 0.83 (95% CI = 0.71–0.98, P = .031).
Impact on R0 Resection Patients
Notably, patients with R0 resection experienced a more pronounced benefit from GemCap. The median overall survival in this subgroup was 49.9 months (95% CI = 39.0–82.3 months) for GemCap compared to 32.2 months (95% CI = 27.9–41.6 months) for gemcitabine, with a hazard ratio of 0.63 (0.47–0.84, P = .002).
Efficacy in Lymph Node-Negative Patients
Further analysis revealed that among lymph node-negative patients, the 5-year overall survival rate was 59% (95% CI = 49%–71%) in the GemCap group versus 53% (95% CI = 42%–66%) in the gemcitabine group (HR = 0.63, 95% CI = 0.41–0.98, P = .04). No significant difference was observed in patients with lymph node-positive disease.
Clinical Implications
The study's findings suggest that GemCap is a valuable treatment option for patients with pancreatic adenocarcinoma (搜索), particularly those who are not eligible for mFOLFIRINOX. According to the investigators, "GemCap is a standard option for patients not eligible for mFOLFIRINOX. Exploratory evidence suggests that GemCap may be particularly efficacious in R0 patients and also in lymph node-negative patients."